Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  BioMérieux    BIM   FR0013280286

BIOMÉRIEUX

(BIM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
116.2(c) 114.7(c) 118.1(c) 116.3(c) 117.5(c) Last
89 701 101 447 145 720 80 092 92 524 Volume
-0.51% -1.29% +2.96% -1.52% +1.03% Change
More quotes
Financials
Sales 2020 3 135 M 3 786 M 3 786 M
Net income 2020 403 M 487 M 487 M
Net Debt 2020 89,8 M 108 M 108 M
P/E ratio 2020 34,7x
Yield 2020 0,39%
Sales 2021 3 303 M 3 988 M 3 988 M
Net income 2021 405 M 489 M 489 M
Net cash position 2021 145 M 175 M 175 M
P/E ratio 2021 34,4x
Yield 2021 0,43%
Capitalization 13 902 M 16 808 M 16 787 M
EV / Sales 2020 4,46x
EV / Sales 2021 4,17x
Nbr of Employees 12 000
Free-Float 31,2%
More Financials
Company
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (82.5%): in industry, microbiological testing of samples from... 
More about the company
Notations Surperformance© of bioMérieux
Trading Rating : Investor Rating :
More Ratings
All news about BIOMÉRIEUX
2020BIOMERIEUX : BIOASTER, Université de Technologie de Compiègne, Hospices Civils d..
PU
2020BIOMERIEUX : The French bioproduction sector announces the creation of Campus Bi..
PU
2020BIOMERIEUX : Increased outlook for full-year 2
PU
2020BIOMERIEUX : BioMérieux Starts COVID-19 Test Kit Sales After Receipt of CE Marki..
MT
2020BIOMÉRIEUX : Announces the CE Marking of Its Molecular Biology ARGENE® Test for ..
BU
2020BIOMERIEUX : Increased outlook for full-year 2020
PU
2020BIOMÉRIEUX : – Increased outlook for full-year 2020
BU
2020BIOMERIEUX : The French bioproduction sector announces the creation of Campus Bi..
PU
2020BIOMERIEUX : bioMérieux announces the expansion of the CE marking of its molecul..
PU
2020BIOMÉRIEUX : Announces the Expansion of the CE Marking of Its Molecular Biology ..
BU
2020BIOMERIEUX : bioMérieux announces the expansion of the CE marking of its molecul..
PU
2020BIOMÉRIEUX : – Third-Quarter 2020 Business Review
BU
2020BIOMÉRIEUX : 3rd quarter earnings
CO
2020BIOMERIEUX : Annual Report 2019
PU
2020BIOMERIEUX : AMSP partners with bioMérieux to facilitate supply of high-quality ..
PU
More news
News in other languages on BIOMÉRIEUX
01/11BIOMERIEUX : LCM a confirmé sa recommandation d'Achat
01/06BIOMERIEUX : plus forte baisse du marché SRD à la clôture du mercredi 6 janvier ..
01/06BIOMERIEUX : plus forte baisse du SBF 120 à la clôture du mercredi 6 janvier 202..
2020BIOMERIEUX : La filière bioproduction française annonce la création du Campus Bi..
2020BIOMERIEUX : Relèvement des perspectives 2
More news
Analyst Recommendations on BIOMÉRIEUX
More recommendations
Stock Trading Strategies
BIOMÉRIEUX - 2020
A medium term support level to take advantage of
BUY
More Stock Trading Analysis
Chart BIOMÉRIEUX
Duration : Period :
bioMérieux Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMÉRIEUX
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 124,48 €
Last Close Price 117,50 €
Spread / Highest target 31,1%
Spread / Average Target 5,94%
Spread / Lowest Target -43,0%
EPS Revisions
Managers and Directors
NameTitle
Alexandre Mérieux Chairman & Chief Executive Officer
Alain Mérieux Founding Chairman
Guillaume Bouhours EVP-Finance, Purchasing & Information Systems
François Lacoste Executive Director-Research & Development
Mark Miller Executive Director-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
BIOMÉRIEUX1.82%16 808
10X GENOMICS, INC.26.89%19 334
AUTOBIO DIAGNOSTICS CO., LTD.6.89%10 801
DIASORIN S.P.A.-4.41%10 735
NATERA, INC.20.74%10 258
GUANGZHOU WONDFO BIOTECH CO.,LTD0.18%4 726